文章核心观点 HUTCHMED宣布将在2024年美国临床肿瘤学会（ASCO）年会上公布其发现的化合物多项研究的新数据和更新数据 [1] 研究成果 子宫内膜癌研究 - 呋喹替尼联合信迪利单抗用于98例经中心实验室分析为错配修复正常（pMMR）状态的二线及以上子宫内膜癌患者的注册II期研究结果将公布，该研究支持了在中国提交的新药申请（NDA） [2] - 该组合在pMMR状态的晚期子宫内膜癌患者中显示出有意义的疗效改善，安全性可控，中位随访时间15.7个月，87例疗效可评估患者的客观缓解率（ORR）为35.6%（含2例完全缓解），疾病控制率（DCR）为88.5%，缓解持续时间未达到，9个月后仍有80.7%的患者有缓解，98例患者的中位无进展生存期（PFS）为9.5个月，中位总生存期（OS）为21.3个月 [2] 其他研究 - 继2024年2月ASCO全体会议系列会议公布呋喹替尼用于二线胃癌的FRUTIGA III期研究初始数据后，今年ASCO年会将公布关键亚组的进一步更新疗效数据和生活质量数据 [3] - 还将公布FRESCO和FRESCO - 2 III期结直肠癌研究、苏泰达联合用药治疗小细胞肺癌的研究以及ERK1/2抑制剂HMPL - 295的初始临床数据 [3] 研究展示详情 赞助研究 - 《Fruquintinib plus Sintilimab in Treated Advanced Endometrial Cancer (EMC) Patients (Pts) with pMMR Status: Results From a Multicenter, Single - Arm Phase 2 Study》，演讲者/第一作者为Xiaohua Wu，复旦大学附属肿瘤医院，展示编号5619，海报展示 - 妇科癌症3579 [4] - 《Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO - 2》，演讲者/第一作者为Tanios S. Bekaii - Saab，梅奥诊所，海报展示 - 胃肠道癌症 — 结直肠癌和肛门癌 [4] - 《Fruquintinib in Refractory Metastatic Colorectal Cancer》，演讲者/第一作者为Cathy Eng，范德比尔特 - 英格拉姆癌症中心，教育会议：肿瘤学新药：纳入实践 [4] - 《Updates on Abstract 438730: Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second - Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized, Multicenter, Double - Blind, Placebo - Controlled, Phase 3 Study》，演讲者/第一作者为Feng Wang，中山大学肿瘤防治中心，教育会议：ASCO全体会议系列：快速摘要更新 [4] - 《Surufatinib plus PD - 1/L1 inhibitors as maintenance therapy following first line (1L) platinum - based chemotherapy combined with PD - 1/L1 inhibitors in patients (pts) with extensive - stage small cell lung cancer》，演讲者/第一作者为Yi Hu，中国人民解放军总医院，编号e15109，仅发布：发育治疗学 — [4] 研究者发起的研究 - 《First - in - human study of HMPL - 295, an ERK1/2 inhibitor, in patients with advanced solid tumors: dose - escalation results of monotherapy》，编号e15570，仅发布：胃肠道癌症 — 结直肠癌和肛门癌 [5] - 《Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single - arm, prospective phase II trial (RIFLE)》，演讲者为Chen Yajie、Zhang Zhen等，复旦大学附属肿瘤医院等，编号e15564，仅发布：胃肠道癌症 — 结直肠癌和肛门癌 [5] - 《A propensity score matched comparison of fruquintinib (FRU) versus FRU combined with PD - 1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: real - world data》，演讲者为Zhu Xu，北京大学肿瘤医院，编号3561，海报展示 - 胃肠道癌症 — 结直肠癌和肛门癌 [5] - 《Phase Ib/II trial of hepatic arterial infusion chemotherapy (HAIC) in combination with fruquintinib as third - line therapy for refractory unresectable colorectal cancer liver metastases》，演讲者为Jianjun Peng，中山大学附属第一医院，编号3536，海报展示 - 胃肠道癌症 — 结直肠癌和肛门癌 [5] - 《Efficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS - 102) as third - line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study》，编号3543，海报展示 - 胃肠道癌症 — 结直肠癌和肛门癌 [5] - 《A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic arteryinfusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival》，演讲者为Lu Wang、Zhang Ti等，复旦大学附属肿瘤医院等，编号e16021，仅发布：胃肠道癌症 — 胃食管、胰腺和肝胆 [5] - 《Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single - arm, open - label, phase 2 clinical trial》，演讲者为Tao Zhang、Zhenyu Lin，华中科技大学同济医学院附属协和医院，编号TPS3643，海报展示：胃肠道癌症 — 结直肠癌和肛门癌 [5] - 《Short - course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): a multicenter, single - arm, open - label, phase II study》，演讲者为Xianjun Yu，复旦大学附属肿瘤医院，编号e15112，仅发布：发育治疗学 — 分子靶向药物和肿瘤生物学 [5] - 《Fruquintinib plus capecitabine versus capecitabine as first - line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study》，演讲者为Junjie Peng、Wenhua Li，复旦大学附属肿瘤医院，编号3567，海报展示：胃肠道癌症 — 结直肠癌 [5][6] - 《Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second - line therapy in metastatic colorectal cancer: updated results of a》，编号3591，海报展示：胃肠道癌症 — 结直肠癌 [9][10] - 《Comparative analysis of first - line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort》，演讲者为Fuxiang Zhou、Wenbo Wang，武汉大学中南医院 [11][12] - 《Efficacy and safety of fruquintinib - based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study》，编号11528，海报展示：肉瘤 [14][15] - 《Disitamab vedotin combined with fruquintinib in patients with HER2 - expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single - arm study》，演讲者为Hui Xu，武汉大学中南医院，编号e15003，仅发布：发育治疗学 — 分子靶向药物和肿瘤生物学e16297 [16] - 《Surufatinib combined with TAS - 102 in third - or later - line therapy of patients with metastatic pancreatic cancer (mPDAC): an open - Label, single - Arm, phase II Study》，演讲者为Dongsheng Zhang，中山大学肿瘤防治中心，仅发布：胃肠道癌症 — 胃食管、胰腺和肝胆 [16] - 《Surufatinib monotherapy or combined with vinorelbine as a late - line therapy in patients with refractory advanced non - small cell lung cancer (NSCLC)》，演讲者为Yanfang Zheng，广州医科大学附属肿瘤医院，编号e20543，仅发布：肺癌 — 非小细胞转移性 [16] - 《Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer》，演讲者为Liangjun Zhu、Sheng Li，江苏省肿瘤医院，编号e15547，仅发布：胃肠道癌症 — 结直肠癌和肛门癌 [16] - 《Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy: updated analysis》，演讲者为Xing Zhang，中山大学肿瘤防治中心，编号11539，海报展示：肉瘤 [16] - 《Efficacy and safety of Surufatinib combined with EP regimen and Serplulimab in first - line treatment of NEC》，演讲者为Tao Zhang、Zhenyu Lin，华中科技大学同济医学院附属协和医院，编号e15123，仅发布：发育治疗学 — 分子靶向药物和肿瘤生物学 [16][17] - 《Performance of surufatinib in treating advanced neuroendocrine neoplasms: Insights from a real - world study》，演讲者为Qing Zhai、Linhui Zhu，复旦大学附属肿瘤医院等，编号e15124，仅发布：发育治疗学 — 分子靶向药物和肿瘤生物学e16375 [17] - 《Epidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohorts》，演讲者为Susheng Shi、Yaru Wen，中国医学科学院肿瘤医院，仅发布：胃肠道癌症 — 胃食管、胰腺和肝胆e16047 [17] - 《Efficacy and safety of surufatinib, toripalimab, nabpaclitaxel in combination with radiotherapy or surgery in the first - line treatment of esophageal squamous cell cancer: A single - centered prospective clinical trial》，演讲者为Fang Liu、Xiang Huang等，中国人民解放军总医院，胃肠道癌症 — 胃食管、胰腺和肝胆e15127 [17] - 《Efficacy and safety of second - line treatment with surufatinib for anlotinib - resistant radioiodine - refractory differentiated thyroid cancer: An exploratory multicenter study》，上海交通大学附属第六人民医院，仅发布：发育治疗学 — 分子靶向药物和肿瘤生物学 [17] 公司介绍 - HUTCHMED是一家创新的、处于商业阶段的生物制药公司，致力于发现、全球开发和商业化用于治疗癌症和免疫疾病的靶向疗法和免疫疗法 [18] - 公司约有5000名员工，其中肿瘤/免疫学团队约1800人，自成立以来专注于将内部发现的癌症候选药物推向全球患者，已有三种药物在中国上市，其中第一种也在美国上市 [18]